A Phase I/II Trial of BAY 43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 23 May 2013
At a glance
- Drugs Sorafenib (Primary) ; Anastrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 May 2013 Last checked against ClinicalTrials.gov record.
- 11 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.